Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights Aug 15, 2017
Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa Jul 18, 2017
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program Jun 29, 2017
Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa May 30, 2017
Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa May 25, 2017
Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights May 16, 2017
